Streamex Corp. · NASDAQ:STEX
Streamex — BioSig Technologies — Investor Presentation (February 2017)
22 slides from Streamex's investor presentation, Feb 22, 2017
Slide 1: Corporate Presentation 2017
corporate presentation 2017 Symbol: BSGM
Slide 2: Disclaimer
Disclaimer Symbol:BSGM * This presentation contains forward-looking statements including statements that address activities, events or developments that BioSig expects, believes or anticipates will or may occur in the future, such as predictions of financial performance, approvals and launches by Bi
Slide 3: Visibility Leads to Cures
Symbol:BSGM * Visibility Leads to Cures In 1900, a third of all US deaths were from pneumonia, tuberculosis and diphtheria In 2014, less than 1000 people died from these diseases Today heart problems are the number one cause of death Better visualization enabled these successes BioSig is developing
Slide 4: Atrial Fibrillation (AFib) Background
Risk of stroke 4-to 5-fold(5th leading cause of death in US) Symbol:BSGM * Atrial Fibrillation (AFib)Background Normal Heart Rhythm Atrial Fibrillation (as one example of acomplex arrhythmia) Everyone over 40 has a 1 in 4 lifetime risk Affects > 6M in US Rapid/irregular heart rate Complex arrhythmia
Slide 5: Ventricular Tachycardia (VT)
Improved signals should enable more precise treatment and less procedures Ventricular Tachycardia (VT) Symbol:BSGM * Normal Heart Rhythm VentricularTachycardia ≈ 450,000 Sudden cardiac deaths in the US annually Rapid / irregular heartbeat in the ventricles of the heart Rapidly fatal if not reversed
Slide 6: Current Diagnosis to Treatment
Current Diagnosis to Treatment Symbol:BSGM * ECG Medication EP Study Ablation Diagnose ChooseTreatment BioSig’s Focus: Improve Diagnosis Increase Ablation Success
Slide 7: Ablation: One Current Solution for Atrial Fibrillation
Goal: Improve cardiac signal accuracy to reduce costs; repeat procedures Symbol:BSGM * Ablation: One Current SolutionFor Atrial Fibrillation (AFib) Catheter inserted into heart Scars tissue that harbors abnormal heart rhythm Left Atrium Catheter (1)http://journals.lww.com/ajnonline/Fulltext/2015/100
Slide 8: Comparison with Competition
Comparison with Competition Symbol:BSGM * Micro-componentsrevealed Competition in Blue BioSig’s PURE EP™ System in Red Noisy Signal Noisy Signal Low amplitude signals revealed
Slide 9: Large & Fast Growing Market
Driver: Ablation becoming first line of therapy Large & Fast Growing Market Symbol:BSGM * EP Labs: Estimated 5,000 WW; 3,000 in the USBy 2020, expected 422,000 procedures in the US with over $3B in revenues EP Devices Current EP Market is <$4 B worldwide $ in Billions Procedure Growth Procedures
Slide 10: Competitive Landscape: EP Recording Devices
Competitive Landscape EP Recording Devices Symbol:BSGM * ~$1 BILLION Installed Base Our competitors’ technology is dated
Slide 11: PURE EP System Testimonial
Symbol:BSGM * PURE EP System Testimonial "The dynamic range of the system is larger - likely will translate into better ability to see both large and small (frequency and amplitude) signals with similar resolution. This is a major problem with present systems, where in order to see smaller signals,
Slide 12: Path To Market
Path To Market Symbol:BSGM * 2017 2017 2017 2017 2018 Q1 Q2 Q3 Q4 Q1 FDA Review Launch Prep & Production Builds MARKET INTRO Targeted Launch Ver. 1.0 AF SYMPOSIUM HRS Meeting Submit Abstracts 510 (k) Clearance Phase 3Design Refinements Verification Test and Iteration Phase 2Detailed DesignEngineerin
Slide 13: Upcoming Major Company Milestones
Upcoming Major Company Milestones Symbol:BSGM * CATEGORY Q1 Q2 Q3 Q4 PEER REVIEWED PUBLICATIONS ON-GOING CLINICAL TRIALS INDUSTRY SYMPOSIA NEW PATENT APPLICATIONS FDA 510(k) CLEARANCE UPLIST TO NASDAQ Engineering Journal – 1H 2017Cardiology Journal – 1H 2017 Mayo – Advanced Research InitiativeMount
Slide 14: Board of Directors
Symbol:BSGM * Board of Directors Kenneth L. Londoner, MBA Founder, Executive Chairman, Director; Endicott Management Partners, J & W Seligman & Co Gregory D. Cash President, CEO and Director: U.S. Surgical, Boston Scientific, Medtronic Roy T. Tanaka Director; Former CEO of BioSense Webster, Johnson
Slide 15: Proven Management Team
Proven Management Team Symbol:BSGM * Kenneth L. Londoner, MBA Founder, Executive Chairman, Director; Endicott Management Partners, LLC, J & W Seligman & Co Gregory D. Cash President, CEO and Director; Pres: Argent International, NeuroTherm, Heartsine Tech, Vasomedical, Datascope, Eminent Tech; Mgmt:
Slide 16: World-Class Scientific Advisory Board
Symbol:BSGM * World-Class Scientific Advisory Board Andrea Natale, MD, Chairman Executive Medical Director, Texas Cardiac Arrhythmia Institute, St. David’s Medical Center Samuel Asirvatham, MD Professor of Medicine & Vice Chair of Division of Cardiovascular Diseases, Department of Medicine; program
Slide 17: Presentations and Manuscripts from Pre-Clinical Studies
Presentations and Manuscripts from Pre-Clinical Studies Symbol:BSGM * Enhanced Electrophysiology Recording Improves Signal Acquisition and Differentiation Presented by team from Mayo Clinic at the 13th Annual International Dead Sea Symposium (IDSS) in Tel-Aviv and available online, March 2016 – Peer
Slide 18: PURE EP – Development Path Collaborating with Leading Centers
PURE EP – Development Path Collaborating with Leading Centers Symbol:BSGM * June 2011 Concept Developed with Texas Cardiac Arrhythmia Institute June 2013 PURE EP System Proof of Concept (POC) Test at UCLA September 2014 PURE EP System Prototype Test at UCLA December 2014 Visit to Mayo Clinic to plan
Slide 19: EP Sector M&A Activity
EP Sector M&A Activity * Company Proof of Concept Prototype Clinical Data CE Mark FDA Sales Acquirer/Investor Valuation HeartWare • • • • • • Medtronic $1.1 BillionJune 2016 St. Jude Medical • • • • • • Abbott $25 billionApril 2016 Hansen Medical • • • • • • Auris Surgical Robotics $80 millionApril
Slide 20: BioSig Technologies, Inc. Key Company Data
Symbol:BSGM * BioSig Technologies, Inc. (BSGM) OTCQB: BSGMWWW.BIOSIGTECH.COM Key Company Data (2/17/17) Recent price: $1.54 52-week range: $1.05 - $2.20 Primary shares i/o: 23.68 million Float: 11.8 million Market cap: $36.47 million Headquarters: Minneapolis, MN
Slide 21: BioSig Investment Highlights
BioSig Investment Highlights Symbol:BSGM * Large & Growing Cardiac Arrhythmia Patient Population ⇒Ablations Increasing 10%+ Annually $4B Total Addressable Market for EP Devices at 10% Growth Annually ⇒ High Demand for New Technologies World-Class Management Team, Board of Directors & Scientific Advi
Slide 22: Contact BioSig
Contact BioSig Symbol:BSGM * Ken LondonerFounder, Executive Chairman(203) 644-5200 klondoner@biosigtech.comGregory CashPresident & Chief Executive Officer(612) 309-4747gcash@biosigtech.comBrian McLaughlinVP, Corporate Finance & Investor Relations(917) 370-9817 bmclaughlin@biosigtech.com This documen
BioSig Technologies — Investor Presentation (February 2017) on 6ix